Online inquiry

IVTScrip™ mRNA-Anti-ALB&IL6R, 20A11-9mer-ALB11(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ354MR)

This product GTTS-WQ354MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets ALB&IL6R gene. The antibody can be applied in Inflammatory conditions, Systemic lupus erythematosus (SLE) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_000477.7; NM_002190.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 213; 3570
UniProt ID P02768; P08887
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-ALB&IL6R, 20A11-9mer-ALB11(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ354MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ8602MR IVTScrip™ mRNA-Anti-FOLH1, HuJ591-DOTA(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA HuJ591-DOTA
GTTS-WQ9338MR IVTScrip™ mRNA-Anti-TNFRSF18, INCAGN-01876(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA INCAGN-01876
GTTS-WQ6442MR IVTScrip™ mRNA-Anti-HA, CT-P22(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA CT-P22
GTTS-WQ8299MR IVTScrip™ mRNA-Anti-GLP1R, HM-12525A(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA HM-12525A
GTTS-WQ3210MR IVTScrip™ mRNA-Anti-CD70, ARGX-110(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA ARGX-110
GTTS-WQ8016MR IVTScrip™ mRNA-Anti-CD52, GZ-402668(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA GZ-402668
GTTS-WQ760MR IVTScrip™ mRNA-Anti-LOXL2, AB0024(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA AB0024
GTTS-WQ2342MR IVTScrip™ mRNA-Anti-MS4A1, AME-133v(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA AME-133v
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW